Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators.
about
Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?Mechanisms of glutamate transportGlutamate transporter 1: target for the treatment of alcohol dependenceCurrent approaches to enhance glutamate transporter function and expressionSmall-molecule activator of glutamate transporter EAAT2 translation provides neuroprotectionGlutamate as a neurotransmitter in the healthy brainGlutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's diseaseThe preclinical discovery of amyotrophic lateral sclerosis drugs.Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus.Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disordersTranslational enhancers of EAAT2: therapeutic implications for neurodegenerative disease.Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.Astroglia as a cellular target for neuroprotection and treatment of neuro-psychiatric disorders.Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury.Reactive Astrocytes as Drug Target in Alzheimer's Disease.Inhibition of p38 MAPK Signaling Regulates the Expression of EAAT2 in the Brains of Epileptic Rats
P2860
Q24613709-7BF16BB2-4A8F-411C-B3FB-73F0CB415B81Q26770781-759E129E-6CFC-4B9D-B4B3-94E6A345A8BFQ26830761-FD59B6BB-E005-44F2-B769-E49196F44045Q26861666-107E8E76-696E-4281-980E-5C32F92E7909Q26996723-06042B6F-7407-455E-986A-C88049AC5185Q30573062-B0BD38AA-CBC5-4D65-88ED-4F80FB45C92AQ34048502-1EA46B4B-1CB0-4095-B584-9A916A9065D7Q34296136-6068A54C-86BD-45C9-8A9E-C48883522C5CQ34504098-1EC303E4-8F33-410E-8E97-7D14A6F7ACB9Q35161465-36E5EBC2-173D-4257-B22D-4768999EE69AQ36009915-70E33997-77FC-4A04-B773-F45BDA39877FQ36610296-792D30F6-AC1B-4183-8193-26998E3E9A96Q36868552-F6E6A525-D439-4606-A22C-9F7614706473Q37609642-FFF137C7-3857-4B5E-863B-9C0B149EB985Q38512084-BB0B559F-D0F8-42DE-80B7-880451818315Q39181656-6029D190-0157-41DE-9D86-9BC883351B16Q50736416-6150E1E1-A2F8-42C5-8852-47EC608460BCQ55280382-7FB01B1F-4433-46A1-B803-E99A07085909Q59138055-30723777-7684-4190-8320-85FBA01E59FB
P2860
Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Structure-activity relationshi ...... transporter EAAT2 activators.
@ast
Structure-activity relationshi ...... transporter EAAT2 activators.
@en
type
label
Structure-activity relationshi ...... transporter EAAT2 activators.
@ast
Structure-activity relationshi ...... transporter EAAT2 activators.
@en
prefLabel
Structure-activity relationshi ...... transporter EAAT2 activators.
@ast
Structure-activity relationshi ...... transporter EAAT2 activators.
@en
P2093
P2860
P1476
Structure-activity relationshi ...... transporter EAAT2 activators.
@en
P2093
Chien-Liang Glenn Lin
Craig K Colton
Gregory D Cuny
Liching Lai
Ling-Chu Chang
Marcie A Glicksman
Qiongman Kong
Xuechao Xing
P2860
P304
P356
10.1016/J.BMCL.2011.08.009
P407
P577
2011-08-08T00:00:00Z